[1] LIU L,ZHU G.Gut-brain axis and mood disorder［J］.Front Psychiatry,2018,9:223.
[2]TRICARICO PM,GRATTON R,DOS SANTOS-SILVA CA,et al.A rare loss-of-function genetic mutation suggest a role of dermcidin deficiency in hidradenitis suppurativa pathogenesis［J］.Front Immunol,2022,13:1060547.
[3] SUN Y,TANG Z,HAO T,et al.Simulated digestion and fermentation in vitro by obese human gut microbiota of sulforaphane from broccoli seeds［J］.Foods(Basel,Switzerland),2022,11(24):4016.
[4] YANG H,XIU W,LIU J,et al.Characteristics of the intestinal microorganisms in middle-aged and elderly patients:Effects of smoking［J］.ACS Omega,2022,7(2):1628-1638.
[5] NEJMAN D,LIVYATAN I,FUKS G,et al.The human tumor microbiome is composed of tumor type-specific intracellular bacteria［J］.Science(New York,N.Y.),2020,368(6494):973-980.
[6] COUSSENS LM,WERB Z.Inflammation and cancer［J］.Nature,2002,420(6917):860-867.
[7] YANG Y,LI L,XU C,et al.Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis［J］.Gut,2020,70(8):1495-1506.
[8] WU J,LI Q,FU X.Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity［J］.Transl Oncol,2019,12(6):846-851.
[9] TANIGUCHI K,KARIN M.NF-κB,inflammation,immunity and cancer:coming of age［J］.Nature Reviews Immunology,2018,18(5):309-324.
[10]SHARMA T,GUPTA A,CHAUHAN R,et al.Cross-talk between the microbiome and chronic inflammation in esophageal cancer:potential driver of oncogenesis［J］.Cancer Metastasis Reviews,2022,41(2):281-299.
[11]WANG Y,WAN X,WU X,et al.Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis［J］.Gut Pathog,2021,13(1):2.
[12]KOSTIC AD,CHUN E,ROBERTSON L,et al.Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment［J］.Cell Host Microbe,2013,14(2):207-215.
[13]LAI Y,CHANG Y,MA J,et al.From DNA damage to cancer progression:Potential effects of cytolethal distending toxin［J］.Front Immunol,2021,12:760451.
[14]FAHRER J,HUELSENBECK J,JAURICH H,et al.Cytolethal distending toxin(CDT) is a radiomimetic agent and induces persistent levels of DNA double-strand breaks in human fibroblasts［J］.DNA Repair(Amst),2014,18:31-43.
[15] GRAILLOT V,DORMOY I,DUPUY J,et al.Genotoxicity of cytolethal distending toxin(CDT) on isogenic human colorectal cell lines:Potential promoting effects for colorectal carcinogenesis［J］.Front Cell Infect Microbiol,2016,6:34.
[16] GUIDI R,GUERRA L,LEVI L,et al.Chronic exposure to the cytolethal distending toxins of Gram-negative bacteria promotes genomic instability and altered DNA damage response［J］.Cell Microbiol,2013,15(1):98-113.
[17] KONTIZAS E,TASTSOGLOU S,KARAMITROS T,et al.Impact of helicobacter pylori infection and its major virulence factor CagA on DNA damage repair［J］.Microorganisms,2020,8(12):2007.
[18] CHATURVEDI R,ASIM M,ROMERO-GALLO J,et al.Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA［J］.Gastroenterology,2011,141(5):1696-708.e1-2.
[19] OECKINGHAUS A,GHOSH S.The NF-kappaB family of transcription factors and its regulation［J］.Cold Spring Harb Perspect Biol,2009,1(4):a000034.
[20]NEUMANN M,NAUMANN M.Beyond IkappaBs:alternative regulation of NF-kappaB activity［J］.FASEB Journal,2007,21(11):2642-2654.
[21] RINKENBAUGH AL,BALDWIN AS.The NF-κB pathway and cancer stem cells［J］.Cells,2016,5(2):16.
[22] SOLEIMANI A,RAHMANI F,FERNS GA,et al.Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer［J］.Gene,2020,726:144132.
[23] NOMOTO D,BABA Y,LIU Y,et al.Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway［J］.Cancer Lett,2022,530:59-67.
[24] CHEN S,SU T,ZHANG Y,et al.Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7［J］.Gut Microbes,2020,11(3):511-525.
[25] YANG Y,WENG W,PENG J,et al.Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB,and up-regulating expression of microRNA-21［J］.Gastroenterology,2017,152(4):851-866.e24.
[26] YONG X,TANG B,XIAO Y,et al.Helicobacter pylori upregulatesNanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer［J］.Cancer Lett,2016,374(2):292-303.
[27] MENG L,SHI H,WANG Z,et al.The Gamma-glutamyltransferase gene of Helicobacter pylori can promote gastric carcinogenesis by activating Wnt signal pathway through up-regulating TET1［J］.Life Sci,2021,267:118921.
[28] SONG Y,LIU G,LIU S,et al.Helicobacter pylori upregulates TRPC6 via Wnt/β-catenin signaling to promote gastric cancer migration and invasion［J］.Onco Targets Ther,2019,12:5269-5279.
[29] MATLY A,QUINN JA,MCMILLAN DC,et al.The relationship between β-catenin and patient survival in colorectal cancer systematic review and meta-analysis［J］.Critical Reviews in Oncology/Hematology,2021,163:103337.
[30] LI X,HUANG J,YU T et al.Fusobacterium nucleatum promotes the progression of colorectal cancer through Cdk5-activated Wnt/β-catenin signaling［J］.Front Microbiol,2020,11:545251.
[31] RUBINSTEIN MR,WANG X,LIU W,et al.Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin［J］.Cell Host Microbe,2013,14(2):195-206.
[32]ALIZADEH S,ESMAEILI A,OMIDI Y.Anti-cancer properties of Escherichia coliNissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways［J］.Iran J Basic Med Sci,2020,23(7):886-893.
[33]JIANG Y,WANG L,YANG B,et al.Bifidobacterium-derived membrane vesicles inhibit triple-negative breast cancer growth by inducing tumor cell apoptosis［J］.Mol Biol Rep,2023,50(9):7547-7556.
[34]SHINNOH M,HORINAKA M,YASUDA T,et al.Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8［J］.Int J Oncol,2013,42(3):903-911.
[35]WANG XN,NIU MT,FAN JX,et al.Photoelectric bacteria enhance the in situ production of tetrodotoxin for antitumor therapy［J］.Nano Lett,2021,21(10):4270-4279.
[36]ZHOU S,GRAVEKAMP C,BERMUDES D,et al.Tumour-targeting bacteria engineered to fight cancer［J］.Nat Rev Cancer,2018,18(12):727-743.
[37]SHARMA PC,SHARMA D,SHARMA A,et al.Recent advances in microbial toxin-related strategies to combat cancer［J］.Semin Cancer Biol,2022,86(Pt 3):753-768.
[38]YANG CJ,CHANG WW,LIN ST,et al.Salmonella overcomes drug resistance in tumor through P-glycoprotein downregulation［J］.Int J Med Sci,2018,15(6):574-579.
[39] MIYAKE K,MURATA T,MURAKAMI T et al.Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model［J］.Arch Gynecol Obstet,2019,299(6):1683-1690.
[40] MIYAKE K,KIYUNA T,MIYAKE M,et al.Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary(CUP)［J］.Tissue Cell,2018,54:144-149.
[41] KAWAGUCHI K,MIYAKE K,ZHAO M,et al.Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine(GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft(PDOX) nude mouse models［J］.Cell cycle(Georgetown,Tex.),2018,17(16):2019-2026.
[42]GRILLE S,MORENO M,BASCUAS T,et al.Salmonella enterica serovar typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect［J］.Immunology,2014,143(3):428-437.
[43]BARAK Y,SCHREIBER F,THORNE SH,et al.Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing［J］.BMC Cancer,2010,10:146.
[44]KAIMALA S,MOHAMED YA,NADER N,et al.Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity［J］.Cancer Immunol Immunother,2014,63(6):587-599.
[45]HUANG X,PAN J,XU F,et al.Bacteria-based cancer immunotherapy［J］.Adv Sci(Weinh),2021,8(7):2003572.
[46] VIJAY-KUMAR M,AITKEN JD,KUMAR A,et al.Toll-like receptor 5-deficient mice have dysregulated intestinal gene expression and nonspecific resistance to Salmonella-induced typhoid-like disease［J］.Infect Immun,2008,76(3):1276-1281.
[47] PHAN TX,NGUYEN VH,DUONG MT,et al.Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy［J］.Microbiol Immunol,2015,59(11):664-675.
[48]ZHENG JH,NGUYEN VH,JIANG SN,et al.Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin［J］.Sci Transl Med,2017,9(376):eaak9537.
[49]HONG EH,CHANG SY,LEE BR,et al.Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic［J］.Vaccine,2013,31(10):1377-1384.
[50]CHANDRA D,JAHANGIR A,QUISPE-TINTAYA W,et al.Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice［J］.Br J Cancer,2013,108(11):2281-2290.
[51]YU X,LIN C,YU J,et al.Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy［J］.Microb Biotechnol,2020,13(3):629-636.
[52]LOWE DC,SAVIDGE TC,PICKARD D,et al.Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA,aroC,and htrA［J］.Infect Immun,1999,67(2):700-707.
[53]MURAKAMI T,HIROSHIMA Y,MIYAKE K,et al.Efficacy of tumor-targeting Salmonella typhimuriumA1-R against malignancies in patient-derived orthotopic xenograft(PDOX) murine models［J］.Cells,2019,8(6):599.
[54]DUONG MT,QIN Y,YOU SH,et al.Bacteria-cancer interactions:bacteria-based cancer therapys［J］.Exp Mol Med,2019,51(12):1-15.
[55] SAMADI M,MAJIDZADEH-A K,SALEHI M,et al.Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes,suppresses tumor growth,angiogenesis and metastasis in vivo［J］.J Biol Eng,2021,15(1):20.
[56]DIN MO,DANINO T,PRINDLE A,et al.Synchronized cycles of bacterial lysis for in vivo delivery［J］.Nature,2016,536(7614):81-85.
[57] CHEN Y,DU M,YUAN Z,et al.Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy［J］.Nat Commun,2022,13(1):4468.
[58]ZHU X,CHEN S,HU X,et al.Near-infrared nano-optogenetic activation of cancer immunotherapy via engineered bacteria［J］.Advanced Materials(Deerfield Beach,Fla.),2023,35(8):e2207198.
[69]HUANG C,WANG FB,LIU L,et al.Hypoxic tumor radiosensitization using engineered probiotics［J］.Adv Healthc Mater,2021,10(10):e2002207.
[60]ZAI W,KANG L,DONG T,et al.E.coli membrane vesicles as a vatalase carrier for long-term tumor hypoxia relief to enhance radiotherapy［J］.ACS Nano,2021,15(9):15381-15394.
[61]CHANDRA D,SELVANESAN BC,YUAN Z,et al.32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect［J］.Oncotarget,2017,8(13):20729-20740.
[62]QUISPE-TINTAYA W,CHANDRA D,JAHANGIR A,et al.Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer［J］.Proc Natl Acad Sci USA,2013,110(21):8668-8673.
[63]CHEN F,ZANG Z,CHEN Z,et al.Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy［J］.Biomaterials,2019,214:119226.
[64]DU Y,LIN L,ZHANG Z,et al.Drug-loaded nanoparticles conjugated with genetically engineered bacteria for cancer therapy［J］.Biochem Biophys Res Commun,2022,606:29-34.
[65]WANG L,QIN W,XU W,et al.Bacteria-mediated tumor therapy via photothermally-programmed cytolysin A［J］.Expression Small,2021,17(40):e2102932.
[66]DENG X,YANG W,SHAO Z,et al.Genetically modified bacteria for targeted phototherapy of tumor［J］.Biomaterials,2021,272:120809.
[67]YIN C,WANG Z,DAI C,et al.Light-triggered photosynthetic engineered bacteria for enhanced-photodynamic therapy by relieving tumor hypoxic microenvironment［J］.Theranostics,2023,13(5):1632-1648.
[68]ZOABY N,SHAINSKY-ROITMAN J,BADARNEH S,et al.Autonomous bacterial nanoswimmers target cancer［J］.J Control Release,2017,257:68-75.
[69]YE Z,LIANG L,LU H,et al.Nanotechnology-employed bacteria-based delivery strategy for enhanced anticancer therapy［J］.Int J Nanomedicine,2021,16:8069-8086.
[70]ALI MK,LIU Q,LIANG K,et al.Bacteria-derived minicells for cancer therapy［J］.Cancer Lett,2020,491:11-21.
[71]RAMAN V,VAN DESSEL N,HALL CL,et al.Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases［J］.Nat Commun,2021,12(1):6116.
[72]YANG M,CONCEICAO M,CHEN W,et al.Engineered bacteria combined with doxorubicin nanoparticles suppress angiogenesis and metastasis in murine melanoma models［J］.Acta Biomater,2023,158:734-746.
[73]DU Y,LIN L,ZHANG Z,et al.Drug-loaded nanoparticles conjugated with genetically engineered bacteria for cancer therapy［J］.Biochem Biophys Res Commun,2022,606:29-34.
[74] MIYAKE K,KIYUNA T,MIYAKE M,et al.Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary(CUP)［J］.Tissue Cell,2018,54:144-149.
[75] GURBATRI CR,LIA I,VINCENT R,et al.Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies［J］.Sci Transl Med,2020,12(530):eaax0876.
[76] ABEDI MH,YAO MS,MITTELSTEIN DR,et al.Ultrasound-controllable engineered bacteria for cancer immunotherapy［J］.Nat Commun,2022,13(1):1585.
[77]CANALE FP,BASSO C,ANTONINI G,et al.Metabolic modulation of tumours with engineered bacteria for immunotherapy［J］.Nature,2021,598(7882):662-666.
[78]VINCENT RL,GURBATRI CR,LI F,et al.Probiotic-guided CAR-T cells for solid tumor targeting［J］.Science,2023,382(6667):211-218.
[79]PANTELI JT,FORKUS BA,VAN DESSEL N,et al.Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker［J］.Integr Biol(Camb),2015,7(4):423-434.
[80]DANINO T,PRINDLE A,KWONG GA,et al.Programmable probiotics for detection of cancer in urine［J］.Sci Transl Med,2015,7(289):289ra84.
[81]ZHANG Y,XUE X,FANG M,et al.Upconversion optogenetic engineered bacteria system for time-resolved imaging diagnosis and light-controlled cancer therapy［J］.ACS Appl Mater Interfaces,2022,14(41):46351-46361.
[82]TOSO JF,GILL VJ,HWU P,et al.Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma［J］.J Clin Oncol,2002,20(1):142-152.
[83]HASSAN R,ALLEY E,KINDLER H,et al.Clinical response of live-attenuated,listeria monocytogenes expressing mesothelin(CRS-207) with chemotherapy in patients with malignant pleural mesothelioma［J］.Clin Cancer Res,2019,25(19):5787-5798.
[84]BASU P,MEHTA A,JAIN M,et al.A randomized phase 2 study of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer［J］.Int J Gynecol Cancer,2018,28(4):764-772.
[85]LAMM DL.BCG immunotherapy for transitional-cell carcinoma in situ of the bladder［J］.Oncology(Williston Park),1995,9(10):947-965.
[86]ROSSER CJ,TIKHONENKOV S,NIX JW,et al.Safety,tolerability,and long-term clinical outcomes of an IL-15 analogue(N-803) admixed with bacillus calmette-Guérin(BCG) for the treatment of bladder cancer［J］.Oncoimmunology,2021,10(1):1912885.
[87]BALAR AV,KAMAT AM,KULKARNI GS,et al.Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG(KEYNOTE-057):an open-label,single-arm,multicentre,phase 2 study［J］.Lancet Oncol,2021,22(7):919-930.